Cover Image
市場調查報告書

Ggenethon - 產品平台分析

Genethon SA - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 253711
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
Ggenethon - 產品平台分析 Genethon SA - Product Pipeline Review - 2016
出版日期: 2016年12月30日 內容資訊: 英文 42 Pages
簡介

Genethon進行著生物療法的研究與臨床開發,同時進行前臨床及臨床開發設計·製造著基因治療藥。

本報告提供Genethon的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Genethon的基本資料

Genethon概要

  • 主要資訊
  • 企業資料

Genethon:R&D概要

  • 主要的治療範圍

Genethon:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Genethon:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Genethon:藥物簡介

  • G1-XCGD
  • Gene Therapy For Wiskott-Aldrich Syndrome
  • Gene Therapy for Gamma-sarcoglycanopathy
  • Gene Therapy Crigler-Najjar Syndrome
  • Gene Therapy For Alpha-sarcoglycanopathy
  • Gene Therapy For Duchenne Muscular Dystrophy
  • Gene Therapy For Dysferlinopathies
  • Gene Therapy For Fanconi Anemia
  • Gene Therapy for Huntington's Disease
  • Gene Therapy for Radiosensitive Severe Combined Immunodeficiency
  • Gene Therapy for Spinal Muscular Atrophy
  • Gene Therapy For Cardiomyopathy

Genethon:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Genethon:最近的開發平台趨勢

Genethon:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08186CDB

Summary

Global Markets Direct's, 'Genethon SA - Product Pipeline Review - 2016', provides an overview of the Genethon SA's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Genethon SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Genethon SA
  • The report provides overview of Genethon SA including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Genethon SA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Genethon SA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Genethon SA's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Genethon SA
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Genethon SA's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Genethon SA Snapshot
    • Genethon SA Overview
    • Key Facts
  • Genethon SA - Research and Development Overview
    • Key Therapeutic Areas
  • Genethon SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Genethon SA - Pipeline Products Glance
    • Genethon SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Genethon SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Genethon SA - Drug Profiles
    • Cell Therapy to Activate FANC-A for Fanconi Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPK-850 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-1XCGD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Duchenne Muscular Dystrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Sickle Cell Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Dysferlin for Dysferlinopathies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Gamma-Sarcoglycan for Gamma Sarcoglycanopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate SGCA for Alpha-Sarcoglycanopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate UGT1A1 for Crigler-Najjar Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy to Activate WASP for Wiskott-Aldrich Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Genethon SA - Pipeline Analysis
    • Genethon SA - Pipeline Products by Target
    • Genethon SA - Pipeline Products by Route of Administration
    • Genethon SA - Pipeline Products by Molecule Type
    • Genethon SA - Pipeline Products by Mechanism of Action
  • Genethon SA - Dormant Projects
  • Genethon SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Genethon SA, Key Facts
  • Genethon SA - Pipeline by Indication, 2016
  • Genethon SA - Pipeline by Stage of Development, 2016
  • Genethon SA - Monotherapy Products in Pipeline, 2016
  • Genethon SA - Partnered Products in Pipeline, 2016
  • Genethon SA - Partnered Products/ Combination Treatment Modalities, 2016
  • Genethon SA - Phase II, 2016
  • Genethon SA - Preclinical, 2016
  • Genethon SA - Discovery, 2016
  • Genethon SA - Pipeline by Target, 2016
  • Genethon SA - Pipeline by Route of Administration, 2016
  • Genethon SA - Pipeline by Molecule Type, 2016
  • Genethon SA - Pipeline Products by Mechanism of Action, 2016
  • Genethon SA - Dormant Developmental Projects,2016

List of Figures

  • Genethon SA - Pipeline by Top 10 Indication, 2016
  • Genethon SA - Pipeline by Stage of Development, 2016
  • Genethon SA - Monotherapy Products in Pipeline, 2016
  • Genethon SA - Partnered Products in Pipeline, 2016
  • Genethon SA - Pipeline by Top 10 Target, 2016
  • Genethon SA - Pipeline by Route of Administration, 2016
  • Genethon SA - Pipeline by Molecule Type, 2016
  • Genethon SA - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top